The role of abuse-deterrent formulations in countering opioid misuse and abuse

被引:9
|
作者
Nguyen, V. [1 ]
Raffa, R. B. [1 ]
Taylor, R. [2 ]
Pergolizzi, J. V., Jr. [3 ,4 ,5 ]
机构
[1] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA
[2] NEMA Res, Bonita Springs, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19122 USA
[5] Assoc Chron Pain Patients, Houston, TX USA
关键词
abuse; abuse-deterrent formulation; opioids; pain management; HYDROCHLORIDE; RESISTANT; CROSSOVER; THERAPY; TABLETS; ROUTES; IMPACT; SAFETY; SAMPLE; RISKS;
D O I
10.1111/jcpt.12337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objective: Pain is a prevalent, and due to the ageing population, increasing medical problem. Opioids are frequently prescribed to meet the unmet medical need. Unfortunately, with the increase in the legitimate use of opioids, there has been a corresponding increase in abuse. A practical way to retain the pain relief afforded by opioids while decreasing opportunities for abuse is to make it more difficult to extract the opioid from the product or to make it less desirable to do so by designing an abuse-deterrent formulation ( ADF). We provide a brief overview of the strategies and early evidence related to opioid ADFs. Methods: Published and unpublished literature, websites, and other sources were searched for current opioid formulation options, including immediate-release and extended-release products. Each was summarized, reviewed and assessed. Results: The strategies that have been used to design the current opioid ADFs involve one or more of four approaches: a physical barrier; incorporation of an opioid receptor antagonist (e.g. naloxone) that self-limits opioid action when taken in excess amount; inclusion of a noxious agent that is released during inappropriate use; or a pro-drug. What is new and conclusions: Legitimate use of opioid analgesics carries with it certain risks, including the risk of abuse. The new ADFs utilize four major strategies and provide innovative additions to the armamentarium. They likely will become an important part of a comprehensive approach to limiting, although not eliminating, opioid misuse and abuse.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 50 条
  • [41] Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States Lessons Learned From OxyContin
    Cicero, Theodore J.
    Ellis, Matthew S.
    JAMA PSYCHIATRY, 2015, 72 (05) : 424 - 429
  • [42] A New Abuse-Deterrent Opioid - Xtampza ER
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1497): : 77 - 78
  • [43] Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain
    Hale, Martin E.
    Moe, Derek
    Bond, Mary
    Gasior, Maciej
    Malamut, Richard
    PAIN MANAGEMENT, 2016, 6 (05) : 497 - 508
  • [45] Use of prescription opioids with abuse-deterrent technology to address opioid abuse
    Michna, Edward
    Kirson, Noam Y.
    Shei, Amie
    Birnbaum, Howard G.
    Ben-Joseph, Rami
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1589 - 1598
  • [46] ABUSE-DETERRENT FORMULATIONS OF OPIOIDS: EFFECTIVENESS AND ECONOMIC IMPACT
    Siddiqi, S. A.
    Islam, M. Z.
    Siddiqi, K. A.
    Haider, M. R.
    VALUE IN HEALTH, 2018, 21 : S191 - S191
  • [47] Opioid abuse-deterrent strategies: role of clinicians in acute pain management
    Webster, Lynn R.
    Brennan, Michael J.
    Kwong, Louis M.
    Levandowski, Richard
    Gudin, Jeffrey A.
    POSTGRADUATE MEDICINE, 2016, 128 (01) : 76 - 84
  • [48] PREVENTING PROVIDER MISINFORMATION AND IMPROVING OVERSIGHT OF ABUSE-DETERRENT OPIOID FORMULATIONS: A POLICY ANALYSIS
    Adams, Elizabeth T.
    ANNALS OF BEHAVIORAL MEDICINE, 2020, 54 : S57 - S57
  • [49] Abuse-Deterrent Opioids
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1522): : 95 - 96
  • [50] Beta-glucan and arabinogalactan-based xerogels for abuse-deterrent opioid formulations
    Veverka, Miroslav
    Dubaj, Tibor
    Veverkova, Eva
    Simon, Peter
    Husar, Stefan
    Tomanova, Katarina
    Jorik, Vladimir
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 129 : 132 - 139